Skip to content

US · PCSA · BIOTECHNOLOGY

Processa Pharmaceuticals, Inc. (PCSA) intrinsic value and stock valuation

$1.56as of 2026-11-21 · Mkt cap 5.83M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Processa Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values PCSA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PCSA’s statements →

Processa Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Vero Beach, FL 32960 processapharmaceuticals.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-13.56M
20112025
Free cash flow
-$-11.39M
20112025
Total equity
$5.58M-24.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-13.99M-$-12.05M-$-11.46M-$-20.26M-$-12.13M
Net income-$-13.56M-$-11.85M-$-11.12M-$-27.42M-$-11.43M
EPSd-$-10.35M-$-98.75M-$-222.4M-$-914M-$-381M
Operating cash flow-$-11.39M-$-11.25M-$-8.06M-$-9.61M-$-8.72M
Capital expenditure-$0.00-$0.00-$0.00$0.00$0.00
Free cash flow-$-11.39M-$-11.25M-$-8.07M-$-9.61M-$-8.72M
Total assets$7.81M$3.23M$5.79M$8.62M$26.5M
Total debt$0.00$70K$150K$230K$80K
Net debt-$-5.54M-$-1.12M-$-4.56M-$-6.27M-$-16.42M
Total equity$5.58M$1.7M$4.99M$7.47M$25.5M
Cash and short-term investments$5.54M$1.19M$4.71M$6.5M$16.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$870K$0.00
Gross profit$0.00$0.00$0.00-$-870K$0.00
Research and development expenses$7.81M$7.27M$5.8M$10.7M$6.88M
Selling, general and administrative expenses$6.18M$4.78M$5.66M$8.68M$4.69M
Other expenses$0.00$0.00$0.00$0.00$570K
Operating expenses$14M$12.1M$11.5M$19.4M$12.1M
Cost and expenses$14M$12.1M$11.5M$20.3M$12.1M
Interest income$110K$200K$340K$100K$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$790K$790K
Ebitda-$-13.56M-$-11.85M-$-11.12M-$-26.64M-$-10.78M
Operating income-$-13.99M-$-12.05M-$-11.46M-$-20.26M-$-12.13M
Total other income/expenses, net$420K$200K$340K-$-7.17M$180K
Income before tax-$-13.56M-$-11.85M-$-11.12M-$-27.42M-$-11.96M
Income tax expense$0.00$0.00$0.00$0.00-$-530K
Net income-$-13.56M-$-11.85M-$-11.12M-$-27.42M-$-11.43M
Weighted average shares outstanding$1.31M$120K$50K$30K$30K
Weighted average diluted shares outstanding$1.31M$120K$50K$30K$30K
Balance sheet
20252024202320222021
Cash and short-term investments$5.54M$1.19M$4.71M$6.5M$16.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.67M$1.87M$5.63M$8.39M$18.3M
Property, plant and equipment, net$0.00$80K$150K$230K$70K
Goodwill and intangible assets$1.15M$0.00$0.00$0.00$8.06M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.14M$1.36M$150K$230K$8.14M
Total assets$7.81M$3.23M$5.79M$8.62M$26.5M
Accounts payable$1.06M$880K$310K$330K$220K
Short-term debt$0.00$70K$80K$80K$70K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.24M$1.53M$730K$1M$970K
Long-term debt$0.00$0.00$70K$150K$10K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities-$0.00$0.00$70K$150K$10K
Capital lease obligations$0.00$70K$150K$230K$80K
Total liabilities$2.24M$1.53M$800K$1.15M$980K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-100.78M-$-87.22M-$-75.37M-$-64.25M-$-36.82M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.58M$1.7M$4.99M$7.47M$25.5M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$70K$150K$230K$80K
Net debt-$-5.54M-$-1.12M-$-4.56M-$-6.27M-$-16.42M
Cash flow statement
20252024202320222021
Net income-$-13.56M-$-11.85M-$-11.12M-$-27.42M-$-11.43M
Depreciation and amortization$0.00$0.00$0.00$790K$790K
Stock-based compensation$860K$630K$1.06M$8.83M$3.41M
Change in working capital$1.54M-$-110K$610K$540K-$-1.18M
Accounts receivable$0.00$0.00$0.00$70K$10K
Inventory$0.00$0.00$0.00$0.00-$-10K
Accounts payable$180K$570K-$-20K$110K-$-100K
Net cash provided by operating activities-$-11.39M-$-11.25M-$-8.06M-$-9.61M-$-8.72M
Investments in property, plant and equipment-$-850K-$0.00-$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-850K-$0.00-$0.00$0.00$0.00
Common stock issued$16.6M$7.76M$6.32M$0.00$10.1M
Common stock repurchased$0.00-$-20K$0.00-$-390K-$-60K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$16.6M$7.73M$6.27M-$-390K$9.8M
Net change in cash$4.35M-$-3.51M-$-1.8M-$-9.99M$1.08M
Cash at end of period$5.54M$1.19M$4.71M$6.5M$16.5M
Operating cash flow-$-11.39M-$-11.25M-$-8.06M-$-9.61M-$-8.72M
Capital expenditure-$0.00-$0.00-$0.00$0.00$0.00
Free cash flow-$-11.39M-$-11.25M-$-8.07M-$-9.61M-$-8.72M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Processa Pharmaceuticals, Inc.

        Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

        CEO
        George K. Ng
        Employees
        12
        Beta
        0.99

        Explore

        Frequently asked questions

        What is the intrinsic value of Processa Pharmaceuticals, Inc. (PCSA)?

        InvestorsCraft does not currently publish an intrinsic value for PCSA. How the IC value is calculated.

        Is PCSA undervalued?

        InvestorsCraft does not publish an undervaluation signal for PCSA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.